Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

NVO

Novo Nordisk ADR

Jun 08 • 04:00PM ET

41.02

-1.94 -4.52 %

Healthcare • Drug Manufacturers - General • Denmark • Large • NYSE

Jun 07, 7:40 PMNovo Nordisk says over 3 million U.S. prescriptions filled for highest-dose oral Wegovy since Jan. 5 launch

Peers: LLY AZN MRK PFE ABBV JNJ NVS BMY SNY AMGN

| Held by: PVAL PPH AVDE PID WCMI PINK APIE AQEC OZEM CNEQ

Scroll to Statements

Index	-	P/E	9.63	EPS (ttm)	4.26	Insider Own	0.00%	Shs Outstand	3.37B	Perf Week	-6.92%
Market Cap	138.20B	Forward P/E	12.27	EPS next Y	3.34	Insider Trans	-	Shs Float	3.37B	Perf Month	-10.44%
Enterprise Value	157.44B	PEG	-	EPS next Q	0.82	Inst Own	9.78%	Short Float	0.64%	Perf Quarter	3.12%
Income	18.95B	P/S	2.71	EPS this Y	-8.29%	Inst Trans	-3.03%	Short Ratio	1.34	Perf Half Y	-14.52%
Sales	50.91B	P/B	5.82	EPS next Y	0.22%	ROA	24.14%	Short Interest	21.72M	Perf YTD	-19.38%
Book/sh	7.05	P/C	41.45	EPS next 5Y	-0.02%	ROE	73.79%	52W High	81.44 -49.63%	Perf Year	-45.04%
Cash/sh	0.99	P/FCF	21.54	EPS past 3/5Y	26.28% 20.36%	ROIC	38.15%	52W Low	35.12 16.80%	Perf 3Y	-48.55%
Dividend Est.	1.82 (4.43%)	EV/EBITDA	5.94	Sales past 3/5Y	23.19% 19.21%	Gross Margin	81.84%	Volatility	3.41% 2.62%	Perf 5Y	-0.29%
Dividend TTM	1.80 (4.39%)	EV/Sales	3.09	EPS Y/Y TTM	26.24%	Oper. Margin	45.45%	ATR (14)	1.40	Perf 10Y	43.48%
Dividend Ex-Date	Mar 30, 2026	Quick Ratio	0.56	Sales Y/Y TTM	16.79%	Profit Margin	37.23%	RSI (14)	39.24	Recom	2.41
Dividend Gr. 3/5Y	26.98% 19.93%	Current Ratio	0.79	EPS Q/Q	86.54%	SMA20	-7.88%	Beta	0.80	Target Price	48.86
Payout	36.87%	Debt/Eq	0.72	Sales Q/Q	37.63%	SMA50	-1.97%	Rel Volume	1.27	Prev Close	42.96
Employees	68794	LT Debt/Eq	0.59	Earnings	May 06 BMO	SMA200	-15.71%	Avg Volume	16.25M	Price	41.02
IPO	Apr 30, 1981	Option/Short	Yes / Yes	EPS/Sales Surpr.	18.04% 1.50%	Trades		Volume	20,617,128	Change	-4.52%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-26-26	Initiated	Wolfe Research	Peer Perform
Mar-18-26	Initiated	Bernstein	Underperform
Mar-18-26	Initiated	Bernstein	Outperform	$175
Mar-10-26	Downgrade	TD Cowen	Buy → Hold	$42
Mar-03-26	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$40
Mar-02-26	Downgrade	Goldman	Buy → Neutral	$41
Feb-24-26	Downgrade	Kepler	Buy → Hold
Feb-24-26	Downgrade	JP Morgan	Overweight → Neutral
Feb-23-26	Downgrade	Deutsche Bank	Buy → Hold
Feb-12-26	Upgrade	Jefferies	Underperform → Hold
Jan-27-26	Initiated	Citigroup	Neutral
Dec-08-25	Downgrade	Argus	Buy → Hold
Oct-27-25	Resumed	Jefferies	Underperform
Oct-01-25	Upgrade	HSBC Securities	Hold → Buy
Sep-29-25	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$47
Sep-17-25	Upgrade	Berenberg	Hold → Buy
Sep-16-25	Upgrade	Rothschild & Co Redburn	Neutral → Buy
Sep-09-25	Upgrade	Bernstein	Mkt Perform → Outperform
Aug-13-25	Upgrade	BNP Paribas Exane	Underperform → Neutral	$54
Aug-05-25	Downgrade	UBS	Buy → Neutral

Show Previous Ratings

Today 05:32PM	LLY Stock Climbs As Oral GLP-1 Pill Beats Novo Nordisk, AstraZenecas Therapies In Diabetes Trials (Stocktwits)
01:26PM	Novo Drops 3.2% As CEO Eyes Longevity And Aesthetics (GuruFocus.com)
10:30AM	Pfizer's monthly weight loss shot posted side effects similar to Wegovy in mid-stage trial (Quartz)
08:30AM	Novo Nordisk's weight loss pill is hitting 3 million U.S. prescriptions and most users had never tried one before (Quartz)
08:22AM	Novo Nordisk Wegovy pill reaches 3 million U.S. prescriptions (Quartz)
07:01AM	Loading…
07:01AM	ADA 26: Lillys dominance, Pfizers foundational drug and Roches me-too option (BioPharma Dive)
06:42AM	Novo Nordisk shares retreat after ADA conference updates fail to excite investors (NVO) (InvestorsHub)
06:16AM	Eli Lilly stock jumps after late-stage trial of next-generation weight-loss drug (MarketWatch)
05:44AM	Eli Lilly, Novo Both Share Good News on Weight-Loss Drugs. Only One Stock Is Rising. (Barrons.com)
04:58AM	3 potential takeover targets in obesity (Pharma Voice)
04:44AM	Zealand Pharma loses a fifth of its value as many users gave up taking weight-loss drug during trial (MarketWatch)
Jun-07-26 07:35PM	The Wegovy pill is still dominating the GLP-1 pill market (MarketWatch)
Jun-06-26 02:53PM	Tired of nausea or taking a GLP-1 pill every day? These experimental drugs could be better than Zepbound and Wegovy. (MarketWatch)
10:04AM	Pfizer targets obesity market with monthly weight-loss injection data (Investing.com)
Jun-05-26 02:31PM	Novo And Lilly Push Beyond US As Only 1%-2% Use Obesity Drugs Globally (GuruFocus.com)
01:19PM	Loading…
01:19PM	GLP-1 Sales Forecast Jumps To $150 Billion By 2030 (GuruFocus.com)
08:53AM	TD Cowen Raises GLP-1 Sales Forecast To $150B By 2030 Industry Leaders LLY, NVO To Remain Dominant (Stocktwits)
Jun-04-26 01:16PM	This Small-Cap Biotech Just Soared Over 160% What Is The Novo Nordisk Connection? (Stocktwits)
10:22AM	Veru Teams Up With Novo Nordisk for Obesity Combination Therapy Trial (VERU) (InvestorsHub)
12:01AM	ASML Becomes Biggest Company in European History (The Daily Upside)
Jun-03-26 04:12PM	ASML Becomes Europe's Most Valuable Stock Ever (GuruFocus.com)
04:12PM	Denmark GDP Forecast Raised to 3.7% as Exports Power Ahead (GuruFocus.com)
12:07PM	Novo Nordisk is taking its Wegovy pill beyond the U.S. (GuruFocus.com)
09:19AM	Novo Nordisk launches Wegovy pill in UAE, its first global market (Quartz)
09:19AM	Novo Nordisk is taking its new weight loss pill global (Quartz)
06:21AM	Novo Nordisk Expands Wegovy Rollout with Launch of Weight-Loss Pill in UAE (NVO) (InvestorsHub)
04:40AM	Why Is Novo Nordisk Stock Climbing Premarket Today? (Stocktwits)
May-29-26 07:06PM	Hims Insider Makes First Stock Purchase Since 2021 Amid Weight-Loss Drug Pivot (Barrons.com)
10:22AM	Lilly Reopens Zepbound Access For 10 Million US Patients (GuruFocus.com)
06:00AM	Eli Lilly's $1 trillion valuation cements its status as Wall Street's ultimate weight-loss play (Yahoo Finance)
06:14PM	Loading…
May-28-26 06:14PM	Eli Lilly Jumps as CVS Expands Weight-Loss Drug Coverage (GuruFocus.com)
06:07PM	CVS Restores Coverage for Lilly's Zepbound (GuruFocus.com)
03:08PM	Lilly's GLP-1 medications will soon be covered by CVS, potentially opening access for millions of Americans (MarketWatch)
02:07PM	CVS will add these weight-loss options to drug plans (USA TODAY)
12:37PM	Eli Lilly Stock Heads for Record Close. CVS Weight-Loss Drug Coverage Drives It Higher. (Barrons.com)
09:03AM	Novo Nordisk faces complex GLP-1 landscape as oral launch patterns diverge from injectables (Proactive)
07:33AM	Small biotech firms quicker to 'latch onto' AI than big ones, says Tencent Healthcare President (Reuters)
07:30AM	CVS Caremark is reversing course on Eli Lilly's weight loss drugs, adding both its shot and new pill to coverage (Quartz)
07:20AM	CVS Caremark adds Zepbound and Foundayo to insurance coverage (Quartz)
07:09AM	CVS obesity drug deal puts Lilly on equal footing with Novo (BioPharma Dive)
06:49AM	CVS brings back coverage for Lilly's obesity drug Zepbound (Reuters)
04:48AM	LLY, NVO Stocks Led Mays GLP-1 Rally But This Smaller Differentiated Player Got A Bold 160% Upside Call (Stocktwits)
May-27-26 12:43AM	HIMS Stock Heads For Weekly Loss But Ex-Netflix CFO Is Buying The Dip Despite BofAs GLP-1 Warning (Stocktwits)
May-26-26 02:54PM	Hims & Hers faces steep climb to hit 2026 guidance as Wegovy churn risk looms, says BofA (Proactive)
09:25AM	Novo Nordisk and Eli Lilly Just Delivered Potential Breakthrough for Cancer Patients (GuruFocus.com)
May-22-26 11:04AM	Novo Nordisk faces new GLP-1 rival as Eli Lilly's triple agonist sets weight-loss record (Proactive)
08:02AM	Lilly and Novo Weight-Loss Drugs Show Potential Cancer Benefits (GuruFocus.com)
02:24AM	HIMS Stock Extends 3-Day Rally: Hims & Hers Targets GLP-1 Gold Rush In Canada After Novo Nordisk Patent Expiry (Stocktwits)
May-21-26 02:41PM	Lilly Obesity Drug Shows 28% Weight Loss (GuruFocus.com)
02:09PM	Eli Lilly Obesity Drug Delivers Up to 28.3% Weight Loss (GuruFocus.com)
12:15PM	Canada and India now have generic Wegovy. Here's why the U.S. doesn't. (MarketWatch)
09:56AM	Eli Lilly's New GLP-1 Drug Looks Like a Weight-Loss Powerhouse in New Trial (Barrons.com)
09:34AM	New weight-loss shot more powerful than old GLP-1s, Eli Lilly says (USA TODAY)
06:07AM	Lower cost Novo, Lilly weight-loss pills draw patients from compounded drugs, doctors say (Reuters)
01:00AM	Live Longer and Better. Does Medicine's New Obsession Really Work? (Barrons.com)
May-20-26 02:14PM	Denmark GDP Jumps 1.9% as Pharma Sector Drives Growth (GuruFocus.com)
May-18-26 01:30PM	Some people lose far more weight than others on GLP-1s like Wegovy. Here's why. (MarketWatch)
09:02AM	AstraZeneca Wins FDA Approval for $5 Billion Blood Pressure Drug (GuruFocus.com)
08:25AM	Novo Nordisk Eyes Global Push for Wegovy Pill (GuruFocus.com)
08:05AM	Novo Nordisk's Wegovy pill maintains strong lead over Eli Lilly rival despite weekly dip, Citi says (Proactive)
05:21AM	Race intensifies to lead next wave of obesity drugs as trial results loom (Pharma Voice)
May-13-26 07:37AM	Novo Nordisks high-dose Wegovy touts near 28% weight loss in early responders (Clinical Trials Arena)
May-12-26 01:01PM	Hims & Hers shares plunge after surprise loss and revenue miss (GuruFocus.com)
10:30AM	The $59B Quiet Shift Reshaping How Patients Access Care (PR Newswire)
May-11-26 05:49PM	Novo Hands Parkinson's Therapy To $60 Million AI Startup (GuruFocus.com)
04:56PM	Hims & Hers reports surprise loss in Q1, shares dive after hours (Investing.com)
01:30PM	Novo Nordisk is handing its Parkinson's stem cell therapy to a Zuckerberg-backed AI startup (Quartz)
01:24PM	Novo Nordisk transfers Parkinson's cell therapy to Cellular Intelligence (Quartz)
01:05PM	Cellular Intelligence licenses Novos shelved Parkinsons cell therapy programme (Pharmaceutical Technology)
09:02AM	Novo Nordisk GLP-1 pill launch impresses but price erosion keeps Citi on the sidelines (Proactive)
May-08-26 02:22PM	Novo Nordisk India Sales Jump After Price Cuts (GuruFocus.com)
11:42AM	GLP-1 battle heats up between Eli Lilly and Novo Nordisk (Yahoo Finance Video)
10:00AM	Wegovy pill on track for blockbuster status as Novo Nordisk navigates crowded GLP-1 market (Proactive)
09:21AM	Novo Nordisk India Sales Jump 40% As Generic Pressure Builds (GuruFocus.com)
07:34AM	Novos CEO champions record-breaking start for Wegovy pill in US market (Pharmaceutical Technology)
May-07-26 02:39PM	Novo Nordisk Surges 9.2% As Wegovy Pill Fuels Momentum (GuruFocus.com)
02:29PM	Amazon Adds Same-Day Ozempic Pill Delivery (GuruFocus.com)
02:05PM	Amazon Expands GLP 1 Push With Ozempic Pill (GuruFocus.com)
08:46AM	Amazon adds Ozempic pill to pharmacy kiosks with same-day delivery (Quartz)
12:01AM	Scoring 2 Million Prescriptions, Novos GLP-1 Pill Crushes Expectations (The Daily Upside)
May-06-26 03:05PM	Novo Nordisk CEO: Open to deals, we need the broadest pipeline in the world (CNBC TV)
11:06AM	Novo Nordisk surges as Wegovy pill demand crushes estimates (Yahoo Finance Video)
10:54AM	Novo Nordisk Swallows the Competition with Wegovy Pill Surge (Moby)
10:53AM	Novo Nordisk posts mixed quarter despite strong demand (GuruFocus.com)
10:52AM	Novo Nordisk beats estimates, raises guidance on Wegovy pill surge (Proactive)
10:04AM	Sales of Novo Nordisk's New Weight-Loss Pill Are Off To a Strong Start. The Stock Is Rising (Investopedia)
09:15AM	Novo Nordisk Raises Outlook as GLP-1 Demand Stays Strong (GuruFocus.com)
08:15AM	5 Things to Know Before the Stock Market Opens (Investopedia)
07:40AM	Novo Nordisk Q1 2026 earnings beat on Wegovy pill demand (Quartz)
07:40AM	Novo Nordisk beats estimates and shares surge on demand for weight loss pill (Quartz)
06:35AM	Novo Nordisk (NVO) lifts 2026 outlook as obesity drug demand remains strong (InvestorsHub)
06:12AM	Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly. (Barrons.com)
05:27AM	Walt Disney headlines earnings slate (MarketWatch)
03:25AM	Novo Nordisk says the Wegovy pill saw the fastest take-up in weight-loss drug history. (MarketWatch)
03:23AM	European shares advance on Mideast peace deal optimism; earnings on watch (Reuters)
01:41AM	Novo Nordisk: Q1 Earnings Snapshot (Associated Press)
May-05-26 07:49AM	Novo Nordisk Faces Price War as Weight-Loss Pill Demand Rises (GuruFocus.com)
06:27AM	Novo Nordisks Weight-Loss Pill Momentum Faces Pricing Pressure (InvestorsHub)
May-04-26 09:48AM	FDA Reports Liver Failure in Patient Taking Lilly's Foundayo (Barrons.com)
09:04AM	Why Eli Lilly stock is down 3% today: FDA adverse event data explained (Investing.com)

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsvaerd, Denmark.

Executive VPMr. Karsten Munk Knudsen

PresidentMr. Maziar Mike Doustdar B.A.

EVP of R&DDr. Martin Holst Lange

EVP of PeopleMs. Tania Sabroe

Executive VP of Enterprise IT & Quality and Member of Management BoardMs. Thilde Hummel Bogebjerg

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NVO

Novo Nordisk ADR

Upgrade your Finviz experience